The increasing prevalence of cancer and cachexia, especially due to the growing geriatric population, is driving the demand for advanced treatments and pharmaceuticals, which primarily drives the market growth. This is further supported by growing consumer awareness of the availability of new therapeutic agents to treat cancer cachexia.
In addition, changes in patient propensity towards pharmacological, non-pharmacologic treatments and combination therapies to improve lean Body Mass (LBM) through clinical trials serve as another growth-promoting factor. Therefore, widespread use of several appetite stimulants such as megestrol acetate, dexamethasone and methylprednisolone to improve digestion also contributes to the market growth.
All accepted abstracts will be published in respective Allied Academies Journals.
Abstracts will be provided with Digital Object Identifier by
